XML 65 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborations and Licensing Arrangements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2019
May 31, 2018
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2018
Dec. 31, 2019
Oct. 31, 2018
Sep. 30, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services     $ 15,352,000   $ 14,595,000 $ 46,701,000 $ 47,045,000        
Deferred revenue — current     28,867,000     28,867,000     $ 32,503,000    
Prepaid expenses and other current assets     4,616,000     4,616,000     2,889,000    
Accounts receivable, net     4,135,000     4,135,000     3,513,000    
Deferred revenue — long term     1,699,000     1,699,000     $ 8,344,000    
Collaborations and services                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services     8,077,000   8,193,000 24,441,000 29,502,000        
AFREZZA product sales                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services     7,275,000   6,402,000 22,260,000 17,543,000        
Collaboration and License Agreement | Receptor CLA                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue — current     100,000     100,000          
Collaboration and License Agreement | Collaborations and services | Receptor CLA                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services     63,000   62,000 188,000 187,000        
Collaboration and License Agreement | United Therapeutics Corporation                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment received                   $ 45,000,000.0  
Milestone Payment Received     12,500,000                
Potential milestone payments to be receive     12,500,000     12,500,000          
Deferred revenue — current     28,700,000     28,700,000          
Collaboration and License Agreement | United Therapeutics Corporation | Clinical Supplies                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Total transaction price     102,600,000     102,600,000          
Deferred revenue — current     1,200,000     1,200,000          
Prepaid expenses and other current assets     800,000     800,000          
Accounts receivable, net     400,000     400,000          
Collaboration and License Agreement | United Therapeutics Corporation | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Additional option exercise and development milestone payments to be receive     40,000,000.0     40,000,000.0          
Collaboration and License Agreement | United Therapeutics Corporation | Collaborations and services                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services           400,000          
Research Agreement | United Therapeutics Corporation                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment received                     $ 10,000,000.0
Total transaction price     10,000,000.0     10,000,000.0          
Research Agreement | United Therapeutics Corporation | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Potential milestone payments to be receive $ 30,000,000.0       30,000,000.0   30,000,000.0        
Research Agreement | United Therapeutics Corporation | Collaborations and services                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services         158,000 211,000 5,874,000        
Research Agreement | United Therapeutics Corporation | Product Prototype                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Total transaction price     9,000,000.0     $ 9,000,000.0          
Revenue performance obligation, method used           The revenue for the product prototype was recognized using an output method (based on project milestones achieved and surveys of performance completed to date). The Company believed that this method best reflected the measure of progress toward complete satisfaction of the performance obligation.          
Research Agreement | United Therapeutics Corporation | Engineering Consulting Services                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Total transaction price     1,000,000.0     $ 1,000,000.0          
Revenue performance obligation, method used           The revenue for the engineering consulting services was recognized using a ratable method until the obligation was satisfied. The Company believed that this method best reflected the measure of progress toward complete satisfaction of the performance obligation.          
Supply and Distribution Agreement | AFREZZA product sales | Biomm                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services $ 700,000   0 $ 200,000              
License and Distribution Agreement | Foreign Country | India Tax Authority                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Income Taxes Paid               $ 200,000      
Income tax receivable     200,000     $ 200,000          
License and Distribution Agreement | Cipla Ltd                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue — current     100,000     100,000          
Marketing and distribution agreement date   2018-05                  
Deferred revenue     1,800,000     1,800,000          
Deferred revenue — long term     1,700,000     1,700,000          
License and Distribution Agreement | Collaborations and services | Cipla Ltd                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services     $ 36,000   $ 37,000 $ 108,000 $ 111,000